Mediti Pharma Inc. logo

Mediti Pharma Inc.

Mediti Pharma is a project focused company created to develop a single asset, MP-101 and will be managing the trial under a Canadian CTA and US IND. The project is fully financed by TVM Life Science Ventures VII.

Mediti Pharma is developing a compound, MP-101, originally discovered by Eli Lilly and Company for the treatment of Alzheimers disease (AD) psychosis.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://meditipharma.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1255 Boule, Robert-Bourassa,QC,H3B 3X3
Montreal
Canada
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/mediti-pharma-inc.” connections=”true” suffix=””]